ARISTADA is the first and only LAI for schizophrenia to offer a
2-month dosing interval
Support your patients during their transition of care
Ensure medication is on board over the dosing interval.
ARISTADA can be started with the 2-month dose (1064 mg) without prior treatment with monthly long-acting injectables1
- ARISTADA is only to be administered as an intramuscular injection by a healthcare professional
- For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ARISTADA
- For all dosage strengths, administer treatment with oral aripiprazole for 21 consecutive days in conjunction with the first ARISTADA injection
- Dose may be adjusted as needed. When making dose and dosing interval adjustments, the pharmacokinetics and prolonged-release characteristics of ARISTADA should be considered
References: 1. ARISTADA [package insert]. Waltham, MA: Alkermes, Inc; 2018. 2. Data on file. Alkermes, Inc. 3. Hard ML, Mills RJ, Sadler BM, Turncliff RZ, Citrome L. Aripiprazole lauroxil: pharmacokinetic profile of this long-acting injectable antipsychotic in persons with schizophrenia. J Clin Psychopharmacol. 2017;37(3):289-295.